268 related articles for article (PubMed ID: 21816029)
21. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.
Penny MA; Verity R; Bever CA; Sauboin C; Galactionova K; Flasche S; White MT; Wenger EA; Van de Velde N; Pemberton-Ross P; Griffin JT; Smith TA; Eckhoff PA; Muhib F; Jit M; Ghani AC
Lancet; 2016 Jan; 387(10016):367-375. PubMed ID: 26549466
[TBL] [Abstract][Full Text] [Related]
22. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.
Vandoolaeghe P; Schuerman L
Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689
[TBL] [Abstract][Full Text] [Related]
23. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.
Aponte JJ; Aide P; Renom M; Mandomando I; Bassat Q; Sacarlal J; Manaca MN; Lafuente S; Barbosa A; Leach A; Lievens M; Vekemans J; Sigauque B; Dubois MC; Demoitié MA; Sillman M; Savarese B; McNeil JG; Macete E; Ballou WR; Cohen J; Alonso PL
Lancet; 2007 Nov; 370(9598):1543-51. PubMed ID: 17949807
[TBL] [Abstract][Full Text] [Related]
24. Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation.
Osoro CB; Ochodo E; Kwambai TK; Otieno JA; Were L; Sagam CK; Owino EJ; Kariuki S; Ter Kuile FO; Hill J
BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38688566
[TBL] [Abstract][Full Text] [Related]
25. The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease.
Penny MA; Pemberton-Ross P; Smith TA
Malar J; 2015 Nov; 14():437. PubMed ID: 26537608
[TBL] [Abstract][Full Text] [Related]
26. [The malaria vaccine candidate RTS,S/AS is in phase III clinical trials].
Cohen J; Benns S; Vekemans J; Leach A
Ann Pharm Fr; 2010 Nov; 68(6):370-9. PubMed ID: 21073995
[TBL] [Abstract][Full Text] [Related]
27. Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi.
Witte D; Cunliffe NA; Turner AM; Ngulube E; Ofori-Anyinam O; Vekemans J; Chimpeni P; Lievens M; Wilson TP; Njiram'madzi J; Mendoza YG; Leach A
Pediatr Infect Dis J; 2018 May; 37(5):483-491. PubMed ID: 29432383
[TBL] [Abstract][Full Text] [Related]
28. Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study.
Sauboin CJ; Van Bellinghen LA; Van De Velde N; Van Vlaenderen I
Malar J; 2015 Dec; 14():524. PubMed ID: 26702637
[TBL] [Abstract][Full Text] [Related]
29. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.
Olotu A; Fegan G; Wambua J; Nyangweso G; Leach A; Lievens M; Kaslow DC; Njuguna P; Marsh K; Bejon P
N Engl J Med; 2016 Jun; 374(26):2519-29. PubMed ID: 27355532
[TBL] [Abstract][Full Text] [Related]
30. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children.
Ansong D; Asante KP; Vekemans J; Owusu SK; Owusu R; Brobby NA; Dosoo D; Osei-Akoto A; Osei-Kwakye K; Asafo-Adjei E; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Janssens MH; Lievens MJ; Olivier AC; Jongert E; Dubois P; Savarese BM; Cohen J; Antwi S; Greenwood BM; Evans JA; Agbenyega T; Moris PJ; Owusu-Agyei S
PLoS One; 2011 Apr; 6(4):e18891. PubMed ID: 21556142
[TBL] [Abstract][Full Text] [Related]
31. Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission.
Brooks A; Briët OJ; Hardy D; Steketee R; Smith TA
PLoS One; 2012; 7(3):e32587. PubMed ID: 22412892
[TBL] [Abstract][Full Text] [Related]
32. The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models.
Penny MA; Galactionova K; Tarantino M; Tanner M; Smith TA
BMC Med; 2015 Jul; 13():170. PubMed ID: 26219380
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.
Asante KP; Ansong D; Kaali S; Adjei S; Lievens M; Nana Badu L; Agyapong Darko P; Boakye Yiadom Buabeng P; Boahen O; Maria Rettig T; Agutu C; Benard Ekow Harrison S; Ntiamoah Y; Adomako Anim J; Adeniji E; Agordo Dornudo A; Gvozdenovic E; Dosoo D; Sambian D; Owusu-Boateng H; Ato Wilson E; Prempeh F; Vandoolaeghe P; Schuerman L; Owusu-Agyei S; Agbenyega T; Ofori-Anyinam O
Vaccine; 2020 Apr; 38(18):3411-3421. PubMed ID: 32192811
[TBL] [Abstract][Full Text] [Related]
34. From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
Cohen J; Nussenzweig V; Nussenzweig R; Vekemans J; Leach A
Hum Vaccin; 2010 Jan; 6(1):90-6. PubMed ID: 19806009
[TBL] [Abstract][Full Text] [Related]
35. Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care.
Vekemans J; Marsh K; Greenwood B; Leach A; Kabore W; Soulanoudjingar S; Asante KP; Ansong D; Evans J; Sacarlal J; Bejon P; Kamthunzi P; Salim N; Njuguna P; Hamel MJ; Otieno W; Gesase S; Schellenberg D;
Malar J; 2011 Aug; 10():221. PubMed ID: 21816031
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.
Lell B; Agnandji S; von Glasenapp I; Haertle S; Oyakhiromen S; Issifou S; Vekemans J; Leach A; Lievens M; Dubois MC; Demoitie MA; Carter T; Villafana T; Ballou WR; Cohen J; Kremsner PG
PLoS One; 2009 Oct; 4(10):e7611. PubMed ID: 19859560
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study.
Moncunill G; Carnes J; Chad Young W; Carpp L; De Rosa S; Campo JJ; Nhabomba A; Mpina M; Jairoce C; Finak G; Haas P; Muriel C; Van P; Sanz H; Dutta S; Mordmüller B; Agnandji ST; Díez-Padrisa N; Williams NA; Aponte JJ; Valim C; Neafsey DE; Daubenberger C; McElrath MJ; Dobaño C; Stuart K; Gottardo R
Elife; 2022 Jan; 11():. PubMed ID: 35060479
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Datoo MS; Natama MH; Somé A; Traoré O; Rouamba T; Bellamy D; Yameogo P; Valia D; Tegneri M; Ouedraogo F; Soma R; Sawadogo S; Sorgho F; Derra K; Rouamba E; Orindi B; Ramos Lopez F; Flaxman A; Cappuccini F; Kailath R; Elias S; Mukhopadhyay E; Noe A; Cairns M; Lawrie A; Roberts R; Valéa I; Sorgho H; Williams N; Glenn G; Fries L; Reimer J; Ewer KJ; Shaligram U; Hill AVS; Tinto H
Lancet; 2021 May; 397(10287):1809-1818. PubMed ID: 33964223
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial.
Umeh R; Oguche S; Oguonu T; Pitmang S; Shu E; Onyia JT; Daniyam CA; Shwe D; Ahmad A; Jongert E; Catteau G; Lievens M; Ofori-Anyinam O; Leach A
Vaccine; 2014 Nov; 32(48):6556-62. PubMed ID: 25077418
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo MS; Dicko A; Tinto H; Ouédraogo JB; Hamaluba M; Olotu A; Beaumont E; Ramos Lopez F; Natama HM; Weston S; Chemba M; Compaore YD; Issiaka D; Salou D; Some AM; Omenda S; Lawrie A; Bejon P; Rao H; Chandramohan D; Roberts R; Bharati S; Stockdale L; Gairola S; Greenwood BM; Ewer KJ; Bradley J; Kulkarni PS; Shaligram U; Hill AVS;
Lancet; 2024 Feb; 403(10426):533-544. PubMed ID: 38310910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
